Program
lutikizumab
Also written as “Lutikizumab”, “ABT-981” and “Lutikizumab Dose A”.
In AbbVie’s pipeline, IL-1a / 1b
. Its studies are mostly in Hidradenitis Suppurativa · Osteoarthritis · Arthritis, Psoriatic · Arthritis, Rheumatoid · Crohn Disease, led by AbbVie.
Furthest: phase 3, since Jun 17, 202412 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 128 open or running | phase 3since Jun 17, 2024 | Aug 1, 2012 | Dec 2026phase 3 · NCT06468228 |
- Named in AbbVie’s own pipeline as
Lutikizumab
, phase 3, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 1, 2012First study: phase 1 study in OsteoarthritisFirst studyNCT01668511 · 36 enrolled · United States
- Mar 13, 2014Phase 2 study in Osteoarthritis, KneeNCT02087904 · 350 enrolled
- Mar 5, 2015Phase 2 study in OsteoarthritisNCT02384538 · 132 enrolled
- Nov 29, 2021Phase 2 study in Hidradenitis SuppurativaNCT05139602 · 210 enrolled · United States, Australia, Canada and more
- Sep 28, 2023Phase 1 study in Healthy VolunteersNCT06067568 · 50 enrolled · United States
- Oct 2, 2023Phase 2 study in Colitis, UlcerativeNCT06257875 · 156 enrolled · United States, Australia, Austria and more
- Jun 17, 2024Phase 3 study in Hidradenitis SuppurativaNCT06468228 · 1,400 enrolled · United States, Argentina, Australia and more
- Jul 24, 2024Phase 2 study in Hidradenitis SuppurativaNCT06524635 · 60 planned · United States
- Aug 8, 2024Phase 2 study in Crohn DiseaseNCT06548542 · 590 planned · United States, Austria, Belgium and more
- Dec 2, 2024Phase 2 study in Dermatitis, AtopicNCT06718101 · 83 enrolled · United States, Japan, South Korea and more
- Mar 4, 2025Phase 2 study in Arthritis, PsoriaticNCT06865105 · 300 planned · United States, Canada, Czechia and more
- May 7, 2025Phase 2 study in Arthritis, RheumatoidNCT06972446 · 180 planned · United States, Canada, Czechia and more
- Nov 9, 2026Primary completion moved from 2027-12 to 2029-08Date moved laterphase 2 · +20 months · NCT06865105
Ahead
- Dec 2026Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06468228
- Feb 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT06972446
- Feb 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT06524635
- May 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT06718101
TargetBeta
“IL-1a / 1b”the company's pipeline, read by Claude · source
“Interleukin-1 alpha inhibitor; Interleukin-1 beta inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ABBV-1451 | AbbVie | phase 1 | 1 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06972446Arthritis, Rheumatoid · United States, Canada, Czechia and more | 2 | Recruiting | Feb 2027 | 180 |
| NCT06865105Arthritis, Psoriatic · United States, Canada, Czechia and more | 2 | Recruiting | Aug 2029 | 300 |
| NCT06718101Dermatitis, Atopic · United States, Japan, South Korea and more | 2 | Active, not recruiting | May 2027 | 83 |
| NCT06548542Crohn Disease · United States, Austria, Belgium and more | 2 | Recruiting | Jan 2030 | 590 |
| NCT06524635Hidradenitis Suppurativa · United States | 2 | Recruiting | Feb 2027 | 60 |
| NCT06468228Hidradenitis Suppurativa · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 2026 | 1,400 |
| NCT06257875Colitis, Ulcerative · United States, Australia, Austria and more | 2 | Active, not recruiting | Sep 2027 | 156 |
| NCT06067568Healthy Volunteers · United States | 1 | Completed | Feb 26, 2024 | 50 |
| NCT05139602Hidradenitis Suppurativa · United States, Australia, Canada and more | 2 | Active, not recruiting | Dec 2027 | 210 |
| NCT02384538Osteoarthritis | 2 | Completed | Jul 2016 | 132 |
| NCT02087904Osteoarthritis, Knee | 2 | Completed | Jun 7, 2016 | 350 |
| NCT01668511Osteoarthritis · United States | 1 | Completed | Oct 2013 | 36 |
How it is read
Names in the registry
- “Lutikizumab”, 9 entries
- “ABT-981”, 3 entries
- “Lutikizumab Dose A”, 1 entry
- “Lutikizumab Dose B”, 1 entry
Conditions, from the studies’ own filings
- Hidradenitis Suppurativa, 3 studies
- Osteoarthritis, 2 studies
- Arthritis, Psoriatic, 1 study
- Arthritis, Rheumatoid, 1 study
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.